Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-165 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| TAK-165 QD | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TAK-165 | DRUG | Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days. |
Inclusion Criteria: * Have advanced or metastatic cancer which is refractory to standard therapy or subjects for whom there is no known effective therapy. * Have a histologically or cytologically proven diagnosis of a solid tumor known to express HER2. * Have a predicted life expectancy of greater ...
TAK-165 is an investigational small molecule being studied for the treatment of breast neoplasm. It was evaluated in a Phase 1 clinical trial in patients with tumors expressing HER2, including breast, pancreatic, lung, ovarian, and renal neoplasms. The drug is being developed by Takeda Pharmaceutical Company Limited.
TAK-165 targets HER2, as it was studied in subjects with tumors expressing HER2. The Phase 1 trial enrolled patients with HER2-expressing tumors, including breast, pancreatic, lung, ovarian, and renal neoplasms, to evaluate the safety and tolerability of the drug.
TAK-165 is being developed by Takeda Pharmaceutical Company Limited, a company listed on the stock exchange under the ticker TAK. The drug is an investigational small molecule in the oncology therapeutic area.
TAK-165 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized, open-label study. The drug is not approved and remains investigational.
TAK-165 has been studied in one completed clinical trial, NCT00034281, titled "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2." This Phase 1 trial enrolled 16 participants in the United States and included patients aged 18 years and older.
TAK-165 is the primary name for this investigational drug. No alternative names have been reported in the clinical trial record. The drug is being developed by Takeda Pharmaceutical Company Limited for the treatment of HER2-expressing tumors.